{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T02:22:19Z","timestamp":1783390939665,"version":"3.54.6"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Public Health Research Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Orthopaedic Science"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jos.2020.10.017","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:05:02Z","timestamp":1608681902000},"page":"1085-1093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of bone mineral density in reducing fracture risk in patients receiving alendronate plus alfacalcidol therapy"],"prefix":"10.1016","volume":"26","author":[{"given":"Eiji","family":"Itoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3013-7775","authenticated-orcid":false,"given":"Yukari","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Orimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Shiraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9041","key":"10.1016\/j.jos.2020.10.017_bib1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jos.2020.10.017_bib2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0011-393X(02)80065-0","article-title":"Alendronate\/Alfacalcidol Fracture Intervention Study Group. The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial","volume":"63","author":"Kushida","year":"2002","journal-title":"Curr Ther Res"},{"issue":"10","key":"10.1016\/j.jos.2020.10.017_bib3","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"National osteoporosis foundation. Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"issue":"14","key":"10.1016\/j.jos.2020.10.017_bib4","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"J\u00a0Am Med Assoc"},{"issue":"7","key":"10.1016\/j.jos.2020.10.017_bib5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"J\u00a0Am Med Assoc"},{"issue":"18","key":"10.1016\/j.jos.2020.10.017_bib6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jos.2020.10.017_bib7","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jos.2020.10.017_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00774-010-0188-x","volume":"29","author":"Shiraki","year":"2011","journal-title":"J\u00a0Bone Miner Metabol"},{"issue":"6","key":"10.1016\/j.jos.2020.10.017_bib9","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1185\/03007995.2011.580341","article-title":"A-TOP (Adequate Treatment of Osteoporosis) research group. Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02","volume":"27","author":"Orimo","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1016\/j.jos.2020.10.017_bib10","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy. Osteoporosis prevention, diagnosis, and therapy","volume":"285","year":"2001","journal-title":"J\u00a0Am Med Assoc"},{"issue":"6","key":"10.1016\/j.jos.2020.10.017_bib11","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U","article-title":"Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group","volume":"42","author":"Hochberg","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jos.2020.10.017_bib12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.jos.2020.10.017_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00296-004-0454-0","article-title":"Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol","volume":"24","author":"Ringe","year":"2004","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.jos.2020.10.017_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s007740170001","article-title":"Osteoporosis diagnostic criteria review committee: Japanese society for bone and mineral research. Diagnostic criteria for primary osteoporosis: year 2000 revision","volume":"19","author":"Orimo","year":"2001","journal-title":"J\u00a0Bone Miner Metabol"},{"issue":"9","key":"10.1016\/j.jos.2020.10.017_bib15","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J\u00a0Bone Miner Res"},{"issue":"2","key":"10.1016\/j.jos.2020.10.017_bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/sim.4780110204","article-title":"Statistical validation of intermediate endpoints for chronic diseases","volume":"11","author":"Freedman","year":"1992","journal-title":"Stat Med"},{"issue":"13","key":"10.1016\/j.jos.2020.10.017_bib17","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/(SICI)1097-0258(19970715)16:13<1515::AID-SIM572>3.0.CO;2-1","article-title":"Estimating the proportion of treatment effect explained by a surrogate marker","volume":"16","author":"Lin","year":"1997","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.jos.2020.10.017_bib18","first-page":"64","article-title":"Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture?","volume":"4","author":"Li","year":"2004","journal-title":"J\u00a0Musculoskelet Neuronal Interact"},{"issue":"3","key":"10.1016\/j.jos.2020.10.017_bib19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/JCD:7:3:255","article-title":"Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk","volume":"7","author":"Watts","year":"2004","journal-title":"J\u00a0Clin Densitom"},{"issue":"8","key":"10.1016\/j.jos.2020.10.017_bib20","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/jbmr.1644","article-title":"Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Jacques","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"issue":"3","key":"10.1016\/j.jos.2020.10.017_bib21","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jbmr.1472","article-title":"Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures","volume":"27","author":"Austin","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.jos.2020.10.017_bib22","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jocd.2012.02.005","article-title":"The importance of absolute bone mineral density in the assessment of antiresorptive agents used for the prevention of osteoporotic fractures","volume":"15","author":"Kuroda","year":"2012","journal-title":"J\u00a0Clin Densitom"},{"issue":"5","key":"10.1016\/j.jos.2020.10.017_bib23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00296-006-0288-z","article-title":"Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial)","volume":"27","author":"Ringe","year":"2007","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.jos.2020.10.017_bib24","first-page":"34","article-title":"Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass","volume":"11","author":"Felsenberg","year":"2011","journal-title":"J\u00a0Musculoskelet Neuronal Interact"},{"issue":"9","key":"10.1016\/j.jos.2020.10.017_bib25","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1258\/ebm.2010.010014","article-title":"Vitamin D nutritional policy needs a vision for the future","volume":"235","author":"Norman","year":"2010","journal-title":"Exp Biol Med"},{"issue":"2","key":"10.1016\/j.jos.2020.10.017_bib26","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1532-5415.2004.52060.x","article-title":"Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily","volume":"52","author":"Dukas","year":"2004","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"8","key":"10.1016\/j.jos.2020.10.017_bib27","first-page":"519","article-title":"Effect of a six-month therapy with alfacalcidol on muscle power and balance and the number of fallers and falls","volume":"60","author":"Dukas","year":"2010","journal-title":"Arzneimittelforschung"},{"issue":"10","key":"10.1016\/j.jos.2020.10.017_bib28","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00296-008-0835-x","article-title":"Potential of alfacalcidol for reducing increased risk of falls and fractures","volume":"29","author":"Ringe","year":"2009","journal-title":"Rheumatol Int"},{"issue":"16","key":"10.1016\/j.jos.2020.10.017_bib29","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.291.16.1999","article-title":"Effect of vitamin D on falls: a meta-analysis","volume":"291","author":"Bischoff-Ferrari","year":"2004","journal-title":"J\u00a0Am Med Assoc"}],"container-title":["Journal of Orthopaedic Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0949265820303328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0949265820303328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T19:32:44Z","timestamp":1760556764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0949265820303328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0949265820303328"],"URL":"https:\/\/doi.org\/10.1016\/j.jos.2020.10.017","relation":{},"ISSN":["0949-2658"],"issn-type":[{"value":"0949-2658","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of bone mineral density in reducing fracture risk in patients receiving alendronate plus alfacalcidol therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Orthopaedic Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jos.2020.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Japanese Orthopaedic Association. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}